The Conference will be of interest to clinicians, medical scientists from academia, pharmaceutical and biotech companies, and public health experts.
It will address both pre-clinical and clinical advances in therapeutic and prophylactic agents for influenza, RSV and other respiratory viruses spanning antivirals, monoclonal and polyclonal antibodies and immunomodulatory agents.
It will also include consideration of clinical development pathways, trial design and study endpoints as well as regulatory issues central to advancing such agents to clinical practice.
The programme will encompass the following topics:
• Preclinical Development
• Clinical Trial Design and Regulatory Issues
• Clinical Trial Papers
• Pathogenesis, Biomarkers and Diagnostics
• Updates on Emerging Threats and Therapeutics and Antiviral Resistance
The preliminary programme can be found here: https://goo.gl/cohPMN
Early Non-Member Registration $850 To 14 September 2018
Early ISIRV Member Registration $700 To 14 September 2018
Late Non-Member Registration $995 To 5 November 2018
Late ISIRV Member Registration $845 To 5 November 2018
Student Registration $400 To 5 November 2018